In recent years, several peptides, such as T-20 (also called DP178),Kilby, J. M., et al., Nat. Med. (1991) 4:1302–1307Wild, C. T., et al., Proc. Natl. Acad. Sci. USA (1994) 91:9770-9774Derdeyn, C. A., et al., J. Virol. ( 2000) 74:8358-8367 Eptifibatide, Ziconotide, Pramlintide, Exenatide, and Bivalirudin, have been approved by the U.S. Food and Drug Administration and are on the market for use in the treatment of various diseases. More importantly, at the end of 2004, more than 600 peptides were either in development or advanced preclinical phases.Marx, V. Chem Eng News 2005, 83, 17-24
